New funding will support the
rapid growth of Aphea.Bio, solidifying its position as a frontrunner in biological product
development for agriculture.
Gent, Belgium, 11 July 2023 - Aphea.Bio, a Belgium-based
agricultural technology company, announced today the successful closing of its Series C Funding
round, securing € 70 million. The round was led by Innovation Industries, joined by Korys
Investments and supported by Bill & Melinda Gates Foundation, SFPIM, BNP Paribas Fortis and
received strong support from returning investors ECBF, Astanor, AIF as well as other existing
The funding will allow Aphea.Bio to further advance research and development in biologicals,
scale product launches, expand market reach and commercialise product offerings. The Company's
partnership with the Gates Foundation will support the development of biostimulant products
designed to address the unique needs of smallholder farmers in the foundation's priority
geographies in Sub-Saharan Africa and South Asia.
Caaj Greebe, Partner at lead investor Innovation Industries states, "Aphea.Bio possesses several
qualities that we actively seek in a company: a world-class team, strong scientific foundations,
and promising products that can effectively tackle the significant challenges faced in modern
agricultural practices. We are thrilled to have led this financing round alongside an
exceptional group of investors to support Aphea.Bio in its next phase of growth towards a global
David Devigne, Investment Director at Korys Investments states, "We are delighted to support
Aphea.Bio in driving the biological revolution in agriculture. Aphea.Bio's ultimate goal of
addressing the ever-increasing challenge of supplying the growing world population with
sufficient and healthy food while using less land and pesticides fully aligns with Korys'
Isabel Vercauteren, CEO of Aphea.Bio says: "We are excited to have secured Series C Funding,
which not only validates our mission to enable sustainable, profitable, and reliable farming,
but also propels us toward commercialisation. This investment will allow us to broaden our
operations and bring our products to market at a larger scale, so we can address urgent
agricultural challenges and meet the needs of farmers worldwide, while at the same time ensuring
accessibility and affordability for smallholder farmers in low-income countries."
This new round of funding comes at a time of remarkable growth for Aphea.Bio. The company has
grown into a diverse and talented team of over 50 scientists and industry specialists, and is
further expanding its research facilities, with a new pilot plant set to open later this year.
Moreover, Aphea.Bio is now a Certified B Corporation™, recognised for demonstrating high
and environmental impact standards.
In addition to these milestones, Aphea.Bio has also made significant strides in its product
portfolio. The recent successful launch of ΛCTIV by Aphea.Bio®, a novel biostimulant
treatment, marked the company's first entry into the market. Looking ahead, Aphea.Bio is now
actively preparing the launch of its first maize biostimulant in 2024 and is planning to submit
its first biofungicide for regulatory approval in the United States and Europe in Q1 and Q3 of
next year, respectively.
Aphea.Bio's recent achievements, coupled with the successful Series C Funding, solidify the
company's position as a key player in achieving a safe and healthy food chain through
Aphea.Bio is a fully integrated microbial product development company dedicated to food security
and ensuring a safe and healthy food chain and is providing novel, science-based solutions to
build the agriculture of the future: sustainable, reliable, and profitable. Located in Gent,
Belgium, we have a highly dedicated and qualified team of scientist and industry experts. Based
on our unique high throughput APEX® R&D platform utilising the untapped microbial space, we have
been able to build a broad biostimulant and biocontrol pipeline based on naturally occurring
We believe that with a fresh and sincere spirit of innovation, result-driven science, and the
courage to go off the beaten track, there is fertile ground to develop efficacious biological
solutions to help complement or partially replace products in the major chemical indications. To
learn more, visit www.aphea.bio or follow us on LinkedIn at www.linkedin.com/company/aphea-bio.
Head of Regulatory Affairs | Communications
Data protection is important to us. You are receiving this publication on the legal basis of
6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive
information about Aphea.Bio, just send us a brief informal message and we will no longer process
details for this purpose. You can also find further details in our privacy statement.
Cautionary Statement Regarding Forward-Looking Statements
This document may contain forward-looking statements, which can be identified by terminology
'expect', 'would', 'will', 'potential',
'prospects', 'estimated', 'aiming', 'on track' and
expressions. Such statements may be subject to risks and uncertainties that could cause the
results to differ materially from these statements. For Aphea.Bio, such risks and uncertainties
include risks relating to legal proceedings, regulatory approvals, new product development,
increasing competition, customer credit risk, general economic and market conditions, compliance
remediation, intellectual property rights, implementation of organizational changes, impairment
intangible assets, consumer perceptions of genetically modified crops and organisms or crop
protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity
single source supply arrangements, political uncertainty, natural disasters, and breaches of
security or other disruptions of information technology. Aphea.Bio assumes no obligation to
forward-looking statements to reflect actual results, changed assumptions or other factors.
© Aphea.Bio, Technologiepark Zwijnaarde 21, 9052 Zwijnaarde.